Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin-containing Regimens for Latent Tuberculosis Infection in Kidney Transplant Recipients
NCT05588492Phase 4Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifamycin SV-MMX in latent tuberculosis infection (LTBI), sponsored by National Taiwan University Hospital. Started Jan 2022; status: recruiting.
02
Drugs
rifamycin SV-MMX
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT05588492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588492.